Kiora Pharmaceuticals, Inc. (KPRX)
After hours:
- Newsfile
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available for virtual 1x1 meetings, and select companies will participate in webcast presentations. Participating companies include; Spire Global (NYSE: SPIR), ...
- Newsfile
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Encinitas, California--(Newsfile Corp. - May 20, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in two upcoming investor conferences that will be available to investors live with the replay available on-demand. On Wednesday May 22, at 3:00 pm Eastern Time, Kiora's Executive Vice President of Finance, Melissa Tosca, will participate in the WeBull Corporate Connect Biotech Investment Webinar. The presentation will be available live from this
- Newsfile
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be initiated in Q4 2024Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 Ended Q1 2024 with $31.3 million in cash and cash equivalents, providing an expected runway of more than two yearsEncinitas, California--(Newsfile Corp. - May 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announces ...
